Dynamic Technology Lab Private Ltd lessened its stake in shares of Embecta Corp. (NASDAQ:EMBC – Free Report) by 6.4% in the 3rd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 21,391 shares of the company’s stock after selling 1,453 shares during the period. Dynamic Technology Lab Private Ltd’s holdings in Embecta were worth $302,000 as of its most recent filing with the Securities & Exchange Commission.
A number of other institutional investors have also recently made changes to their positions in EMBC. Vanguard Group Inc. boosted its stake in Embecta by 2.7% during the first quarter. Vanguard Group Inc. now owns 7,213,992 shares of the company’s stock valued at $95,730,000 after buying an additional 187,916 shares during the last quarter. American Century Companies Inc. grew its holdings in shares of Embecta by 0.6% in the second quarter. American Century Companies Inc. now owns 3,163,073 shares of the company’s stock valued at $39,538,000 after purchasing an additional 18,933 shares in the last quarter. Bank of New York Mellon Corp grew its holdings in shares of Embecta by 1.6% in the second quarter. Bank of New York Mellon Corp now owns 793,585 shares of the company’s stock valued at $9,920,000 after purchasing an additional 12,424 shares in the last quarter. AQR Capital Management LLC raised its stake in Embecta by 136.2% during the second quarter. AQR Capital Management LLC now owns 614,645 shares of the company’s stock valued at $7,683,000 after purchasing an additional 354,454 shares in the last quarter. Finally, Marshall Wace LLP lifted its holdings in shares of Embecta by 15.2% in the 2nd quarter. Marshall Wace LLP now owns 479,515 shares of the company’s stock valued at $5,994,000 after acquiring an additional 63,169 shares during the last quarter. Hedge funds and other institutional investors own 93.83% of the company’s stock.
Wall Street Analyst Weigh In
Separately, BTIG Research upgraded Embecta from a “neutral” rating to a “buy” rating and set a $26.00 price target for the company in a research report on Wednesday, November 27th.
Embecta Trading Up 1.2 %
NASDAQ:EMBC opened at $20.83 on Monday. The stock has a fifty day simple moving average of $14.68 and a 200-day simple moving average of $14.21. The company has a market cap of $1.20 billion, a price-to-earnings ratio of 15.43 and a beta of 0.97. Embecta Corp. has a twelve month low of $9.93 and a twelve month high of $20.86.
Embecta Announces Dividend
The business also recently announced a quarterly dividend, which will be paid on Wednesday, December 18th. Shareholders of record on Friday, December 6th will be paid a $0.15 dividend. The ex-dividend date of this dividend is Friday, December 6th. This represents a $0.60 dividend on an annualized basis and a yield of 2.88%. Embecta’s dividend payout ratio is currently 44.44%.
About Embecta
Embecta Corp., a medical device company, focuses on the provision of various solutions to enhance the health and wellbeing of people living with diabetes. Its products include pen needles, syringes, and safety injection devices, as well as digital applications to assist people with managing patient's diabetes.
Further Reading
- Five stocks we like better than Embecta
- What Is WallStreetBets and What Stocks Are They Targeting?
- Analog Devices: Why the Uptrend Could Accelerate in 2025
- What is a buyback in stocks? A comprehensive guide for investors
- Texas Pacific Land: Permian Basin Powerhouse With an AI Edge
- Buy P&G Now, Before It Sets A New All-Time High
- ServiceNow: Will the High-Flyer Finally Split in 2024?
Receive News & Ratings for Embecta Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Embecta and related companies with MarketBeat.com's FREE daily email newsletter.